Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics director Nima Farzan sold shares in a planned trade. On June 4, 2026, he sold 2,625 shares of Keros Therapeutics common stock in an open-market transaction at a weighted average price of $10.73 per share.
The sale was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-arranged. After these transactions, Farzan directly owns 9,767 shares of Keros Therapeutics common stock.
Keros Therapeutics director Julius Knowles reported an open-market sale of 2,625 shares of Common Stock at a weighted average price of $10.73 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Following the sale, Knowles holds 10,958 shares directly. In addition, 102,233 shares are held indirectly through Partners Innovation Fund, LLC and 150,047 shares are held indirectly through Partners Innovation Fund II, L.P., where entities associated with him may share voting and investment power.
Keros Therapeutics director Alpna Seth received equity-based compensation rather than buying shares on the market. On this Form 4, Seth was granted 7,142 restricted stock units of common stock and a stock option for 7,433 shares at an exercise price of $10.50 per share.
The RSUs vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, as long as she continues providing service. The option vests in equal quarterly installments over 12 months following June 3, 2026, and will in any case be fully vested by the 2027 annual meeting, also subject to continued service. After these grants, she directly holds 12,392 common shares and 7,433 options.
Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 shares of common stock at a weighted average price of $10.72 per share on June 4, 2026. The shares were sold in multiple trades between $10.60 and $10.89. After this transaction, she directly holds 9,767 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was planned in advance.
Keros Therapeutics director Mary Ann Gray received new equity awards. She was granted 7,142 shares of common stock in the form of restricted stock units that fully vest on the earlier of June 3, 2027 or the 2027 annual meeting, subject to continued service. She also received options for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over 12 months after June 3, 2026 and fully vested by the 2027 annual meeting. Following the RSU grant, she directly holds 12,392 common shares.
Keros Therapeutics director Nima Farzan reported equity awards that increase his direct stake in the company. He received 7,142 shares of common stock through a restricted stock unit (RSU) grant, bringing his direct common stock holdings to 12,392 shares.
The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, if he continues to provide service. He was also granted a stock option for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over the 12 months following June 3, 2026 and in any case fully vested by the 2027 annual meeting, subject to continued service. These are compensation-related awards rather than open-market purchases or sales.
Keros Therapeutics director Jean Jacques Bienaime reported equity awards rather than open-market trades. He received 7,142 shares of Common Stock as a restricted stock unit award, bringing his direct Common Stock holdings to 16,592 shares. The filing also shows a grant of options for 7,433 shares of Common Stock at an exercise price of $10.50 per share. The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, while the options vest in equal quarterly installments over 12 months following June 3, 2026 and in any case are fully vested by the 2027 annual meeting, in each case subject to continued service.
Keros Therapeutics director Julius Knowles reported new equity awards and updated his holdings. He received 7,142 restricted stock units that vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, as long as he continues serving the company.
He also received a stock option covering 7,433 shares of common stock at an exercise price of $10.50 per share. This option vests in equal quarterly installments over the 12 months following June 3, 2026 and will in any case be fully vested by the 2027 annual meeting, subject to continued service. After these grants, he directly holds 13,583 common shares and also has indirect interests in 102,233 and 150,047 shares held by Partners Innovation Fund, LLC and Partners Innovation Fund II, L.P., where he may share voting and investment power.